Skin care composition containing ultraviolet wavelength-converting substance and alkylene oxide derivative

Abstract

Provided is a novel skin care composition suited for cell activation.　A skin care composition according to the present disclosure contains an ultraviolet wavelength-converting substance and an alkylene oxide derivative.

Description

Composition for external use on skin containing ultraviolet wavelength converting substance and alkylene oxide derivative

[0001] The present invention relates to a composition for external use on the skin that has cell activation activity and contains an ultraviolet wavelength converting substance and an alkylene oxide derivative, and to an agent for promoting the ultraviolet wavelength converting function of an ultraviolet wavelength converting substance that contains an alkylene oxide derivative as an active ingredient.

[0002] Ultraviolet rays are thought to generate free radicals in the body, causing sebum oxidation and damage to cellular DNA. These effects of ultraviolet rays on the skin can have adverse effects such as skin cancer, photoaging, age spots, wrinkles, and inflammation, which are undesirable from the perspectives of health and beauty.

[0003] In recent years, it has been found that ultraviolet wavelength converting substances not only reduce the harmful effects of ultraviolet rays but also have a cell activation effect. For example, it has been reported that an emulsion composition containing an ultraviolet wavelength converting substance increases the concentration of cytochrome c in human skin-derived fibroblasts when irradiated with sunlight containing ultraviolet rays, thereby enhancing mitochondrial activity and thereby activating the cells (Patent Document 1).

[0004] Alkylene oxide derivatives are known as moisturizing agents that do not leave a sticky feeling, and are used in external skin preparations (Patent Document 2).

[0005] International Publication No. 2020 / 204196 Japanese Patent Application Laid-Open No. 2004-083541

[0006] The object of the present invention is to provide a novel external skin composition having a cell activation effect using ultraviolet light, and to provide an ultraviolet wavelength conversion function promoter of an ultraviolet wavelength conversion substance, which contains an alkylene oxide derivative as an active ingredient.

[0007] The present inventors have conducted extensive research into how to effectively utilize ultraviolet light on the skin. As a result, they have discovered that alkylene oxide derivatives promote the function of ultraviolet wavelength converting substances, and have conceived a novel topical skin composition with excellent cell activation activity, and an ultraviolet wavelength converting function promoter of ultraviolet wavelength converting substances, which contains an alkylene oxide derivative as an active ingredient.

[0008] The present application provides the following invention: [1] A composition for external use on skin, comprising: (A) an ultraviolet wavelength converting substance; and (B) an alkylene oxide derivative represented by the following general formula (I): １ O-[(EO) ｍ (AO) ｎ ]-R ２ (I) (wherein, AO is an oxyalkylene group having 3 to 4 carbon atoms, EO is an oxyethylene group, the oxyalkylene group having 3 to 4 carbon atoms and the oxyethylene group may be added in a block form or in a random form, m and n are the average number of moles of the oxyethylene group and the oxyalkylene group added, respectively, and 1≦m≦70, 1≦n≦70, and 0.2≦m / (m+n)≦0.8, R １ and R ２ are the same or different alkyl groups having 1 to 4 carbon atoms or hydrogen atoms, and R １ and R ２ R relative to the number of alkyl groups １ and R ２ The ratio of the number of hydrogen atoms in the alkylene oxide derivative to the number of hydrogen atoms in the alkylene oxide derivative is 0.15 or less on average. [2] The topical skin composition according to [1], wherein the ultraviolet wavelength converting substance is one or more selected from zinc oxide phosphor, magnesium titanate phosphor, and phycocyanin. [3] The topical skin composition according to [1] or [2], wherein the ultraviolet wavelength converting substance is zinc oxide phosphor and phycocyanin. [4] The topical skin composition according to any one of [1] to [3], wherein the oxyalkylene group and the oxyethylene group of the alkylene oxide derivative are added randomly. [5] The topical skin composition according to any one of [1] to [4], wherein the oxyalkylene group of the alkylene oxide derivative is an oxypropylene group. [6] The topical skin composition according to any one of [1] to [4], wherein the R １ and R ２and R are both methyl groups. [7] The topical skin composition according to any one of [1] to [6], which contains 1 wt % or more of the alkylene oxide derivative. [8] The topical skin composition according to any one of [1] to [7], which is a water-in-oil composition. [9] The topical skin composition according to any one of [1] to [8], which is used for cell stimulating purposes.

[10] An ultraviolet wavelength conversion function promoter of an ultraviolet wavelength conversion substance, which contains an alkylene oxide derivative represented by the following general formula (I) as an active ingredient: R １ O-[(EO) ｍ (AO) ｎ ]-R ２ (I) (wherein, AO is an oxyalkylene group having 3 to 4 carbon atoms, EO is an oxyethylene group, the oxyalkylene group having 3 to 4 carbon atoms and the oxyethylene group may be added in a block form or in a random form, m and n are the average number of moles of the oxyethylene group and the oxyalkylene group added, respectively, and 1≦m≦70, 1≦n≦70, and 0.2≦m / (m+n)≦0.8, R １ and R ２ are the same or different alkyl groups having 1 to 4 carbon atoms or hydrogen atoms, and R １ and R ２ R relative to the number of alkyl groups １ and R ２ The ratio of the number of hydrogen atoms in the alkylene oxide derivative to the number of hydrogen atoms in the alkylene oxide derivative is 0.15 or less on average.

[11] The ultraviolet wavelength conversion function promoter according to

[10] , wherein the ultraviolet wavelength conversion substance is one or more selected from zinc oxide phosphor, magnesium titanate phosphor, and phycocyanin.

[12] The ultraviolet wavelength conversion function promoter according to

[10] or

[11] , wherein the oxyalkylene groups and the oxyethylene groups of the alkylene oxide derivative are added randomly.

[13] The ultraviolet wavelength conversion function promoter according to any one of

[10] to

[12] , wherein the oxyalkylene groups of the alkylene oxide derivative are oxypropylene groups.

[14] The ultraviolet wavelength conversion function promoter according to

[10] , wherein the R １ and R ２

[15] Use of an alkylene oxide derivative represented by the following general formula (I) for promoting the function of an ultraviolet wavelength conversion material: R １ O-[(EO) ｍ (AO) ｎ ]-R ２ (I) (wherein, AO is an oxyalkylene group having 3 to 4 carbon atoms, EO is an oxyethylene group, the oxyalkylene group having 3 to 4 carbon atoms and the oxyethylene group may be added in a block form or in a random form, m and n are the average number of moles of the oxyethylene group and the oxyalkylene group added, respectively, and 1≦m≦70, 1≦n≦70, and 0.2≦m / (m+n)≦0.8, R １ and R ２ are the same or different alkyl groups having 1 to 4 carbon atoms or hydrogen atoms, and R １ and R ２ R relative to the number of alkyl groups １ and R ２ The ratio of the number of hydrogen atoms to the number of hydrogen atoms is 0.15 or less on average.

[0009] The alkylene oxide derivative, which is the ultraviolet wavelength conversion function promoter according to the present invention, is suitable for the ultraviolet wavelength conversion substance to convert ultraviolet rays to visible light, and can obtain strong emitted light (fluorescence). The topical skin composition according to the present invention, which contains the alkylene oxide derivative and the ultraviolet wavelength conversion substance, emits strong fluorescence when irradiated with ultraviolet rays, and can effectively utilize ultraviolet rays to activate skin cells.

[0010] The present invention will be described in detail below with reference to specific embodiments, but the present invention is not limited to the following embodiments and can be embodied in any form without departing from the spirit of the present invention.

[0011] All patent publications, published patent applications, non-patent publications, and other documents cited in this disclosure are hereby incorporated by reference in their entirety into this disclosure for all purposes.

[0012] In this disclosure, when applied to a numerical value, the term "to" refers to a range of values ​​that is equal to or greater than the specified reference value and is equal to or less than the specified reference value.

[0013] (A) UV wavelength conversion substance The topical skin composition of the present invention contains an UV wavelength conversion substance as an active ingredient. The UV wavelength conversion substance refers to a substance that converts the wavelength of UV rays contained in incident light and emits output light with a wavelength longer than the wavelength of the UV rays. The organic UV wavelength conversion substance refers to a UV wavelength conversion substance that is an organic compound, and the inorganic UV wavelength conversion substance refers to a UV wavelength conversion substance that is an inorganic compound.

[0014] The ultraviolet light may include UVA, UVB, UVC, etc. In some embodiments, the ultraviolet light is light having a peak wavelength between 200 nm and 400 nm. Alternatively, the ultraviolet light may be contained in incident light, such as sunlight. Alternatively, the incident light may be ultraviolet light, or artificially generated ultraviolet light may be used.

[0015] The emitted light from the UV wavelength conversion material has a wavelength longer than that of UV light, preferably having a peak wavelength between 450 nm and 700 nm or between 500 nm and 700 nm. The emitted light may have one or more peaks at, for example, but not limited to, 510 nm, 520 nm, 530 nm, 540 nm, 550 nm, 560 nm, 570 nm, 580 nm, 590 nm, 600 nm, 610 nm, 620 nm, 630 nm, 640 nm, 650 nm, 660 nm, 670 nm, 680 nm, 690 nm, 700 nm, or any range therebetween, or may be red light, orange light, green light, blue light, or the like. In some embodiments, the UV wavelength conversion material emits light with a dominant wavelength between 500 nm and 700 nm when excited with excitation light of 200 nm to 400 nm.

[0016] Examples of ultraviolet wavelength conversion substances include the following components: phycobiliproteins such as phycocyanin (allophycocyanin, C-phycocyanin, R-phycocyanin), phycoerythrocyanin, and phycoerythrin (B-phycoerythrin, b-phycoerythrin, C-phycoerythrin, R-phycoerythrin); vitamin A, β-carotene, vitamin K, vitamin B1, vitamin B2, vitamin B6, vitamin B12, and leaves. Naturally derived or synthetic ingredients such as acid, niacin, salicylic acid, lycopene, chili pepper extract, chili pepper pigment, paprika pigment, gardenia pigment, safflower pigment, turmeric pigment, cochineal pigment, perilla pigment, red cabbage pigment, flavonoids, carotenoids, quinoids, porphyrins, anthocyanins, polyphenols, etc.; Red No. 401, Red No. 227, Red No. 504, Red No. 218, Orange No. 205P, Yellow No. 4, Yellow No. 5, Green No. 2 dyes such as No. 01, Pyranine Concentrate, Blue No. 1, 2,4-diaminophenoxyethanol hydrochloride, Alizurin Purple SS, Purple No. 401, Black No. 401, Herringdon Pink, Yellow No. 401, Benzidine Yellow G, Blue No. 404, Red No. 104, and meta-aminophenol; fluorescent substances obtained by doping inorganic compounds with fluorescence, such as amorphous silica particles described in Patent No. 6,424,656, with cerium, phosphorus, and / or magnesium; and a red phosphor comprising a compound obtained by activating a europium-activated mixed crystal of an alkaline earth metal sulfide and a gallium compound described in Japanese Patent No. 6361416; a zinc oxide phosphor described in International Publication No. 2018 / 004006; a zinc oxide phosphor described in Japanese Patent Application Laid-Open No. 2018-131422; an inorganic phosphor described in Japanese Patent Application Laid-Open No. 5-117127; and the like (hereinafter, a phosphor derived from zinc oxide will be referred to as a "zinc oxide phosphor"). In one embodiment, the inorganic phosphor is ZnO:Zn,Zn １＋ｚ , ZnO １－ｘ A phosphor doped with a sulfur-containing compound such as a sulfide salt and / or sulfate, for example, zinc sulfide or zinc sulfate, as described in WO 2018 / 004006; MgTiO ３ , Mg ２ TiO ４Magnesium titanate phosphors obtained by doping magnesium titanate such as the above with manganese (hereinafter, phosphors derived from magnesium titanate will be referred to as "magnesium titanate phosphors"); and Ca(H ２ P.O. ４ ) ２ , CaHPO ４ , Ca ３ (P.O. ４ ) ２ The phosphor is one or more phosphors selected from calcium phosphate phosphors obtained by doping calcium phosphate with cerium, such as:

[0017] Furthermore, the inorganic ultraviolet wavelength conversion material, which is an inorganic phosphor, may be surface-treated, for example, with a silane compound (such as octyltriethoxylane), a silicone compound, a fluorine-modified silicone compound, a fluorine compound, a higher fatty acid (such as stearic acid), a higher alcohol, a fatty acid ester, a metal soap, an amino acid, or an alkyl phosphate.

[0018] Ultraviolet wavelength conversion substances may be obtained by methods such as extraction from natural products such as animals, plants, and algae, or by artificial methods such as chemical synthesis. For example, phycobiliproteins may be prepared by extracting algae such as blue-green algae such as Spirulina platensis or red algae such as Porphyridium purpureum using methods described in, for example, Japanese Patent Nos. 4048420, 4677250, and 3303942. Zinc oxide phosphors may be produced using methods such as those described in International Publication No. 2018 / 004006, Japanese Patent Application Publication No. 2018-131422, and Japanese Patent Application Publication No. 5-117127. Magnesium titanate phosphors may be produced using methods described in Japanese Patent Application Publication No. 2017-88719. The calcium phosphate phosphor may be produced by the method described in WO 2018 / 117117.

[0019] These ultraviolet wavelength conversion substances may be composed of or contain the above-mentioned components, and may be used alone or in combination, as long as they do not impair the wavelength conversion effect of the present invention. For example, they may contain phycobiliproteins such as phycocyanin and inorganic phosphors such as zinc oxide phosphors. Furthermore, phycobiliproteins or inorganic phosphors may be mixed with other ultraviolet wavelength conversion substances, such as vitamin B (vitamin B1, vitamin B2, vitamin B6, vitamin B12, etc.), to achieve a synergistic effect. However, these components are merely examples, and any substance that exhibits the wavelength conversion effect of the present invention can be used.

[0020] Vitamin B2, which is an ultraviolet wavelength converting substance, may be a derivative thereof as long as it is an ultraviolet wavelength converting substance. Examples of vitamin B2 derivatives include riboflavin acetate, riboflavin butyrate, riboflavin phosphate (which may be a salt of sodium or monodiethanolamine), flavin mononucleotide, flavin adenine dinucleotide, riboflavin tetrabutyrate, and riboflavin tetranicotinate, and may also be a derivative of lyxoflavin, a stereoisomer of riboflavin.

[0021] The content of the ultraviolet wavelength converting substance in the topical skin composition of the present invention is not particularly limited as long as it does not impair the wavelength conversion effect of the present invention, and can be appropriately determined depending on the type of ultraviolet wavelength converting substance and the intended use of the topical skin composition containing the ultraviolet wavelength converting substance, for example, within ranges of 0.001 to 99.99 wt %, 0.001 to 10 wt %, 0.01 to 99.99 wt %, 0.01 to 10 wt %, 0.1% to 99.9 wt %, 0.1 to 10 wt %, etc.

[0022] In one embodiment of the present invention, the ultraviolet wavelength converting substance in the topical skin composition comprises a zinc oxide phosphor, and the content of the zinc oxide phosphor in the topical skin composition of the present invention is preferably 0.1 wt% or more, preferably 1.0 wt% or more, more preferably 1.5 wt% or more, even more preferably 2 wt% or more, and 20 wt% or less, preferably 15 wt% or less, more preferably 10 wt% or less, even more preferably 5 wt% or less, and is 0.01 to 99.99 wt%, 0.1 to 99.9 wt%, 0.1 to 50 wt%, 0.1 to 40 wt%, 0.1 to 30 wt%, 0.1 to 20 wt%, 0.1 to 10 wt%, or 1 to 10 wt% relative to the total topical skin composition.

[0023] In one embodiment of the present invention, the ultraviolet wavelength converting substance in the topical skin composition comprises a magnesium titanate phosphor, and the content of the magnesium titanate phosphor in the topical skin composition of the present invention is preferably 0.1 wt% or more, preferably 1.0 wt% or more, more preferably 1.5 wt% or more, even more preferably 2 wt% or more, and 20 wt% or less, preferably 15 wt% or less, more preferably 10 wt% or less, even more preferably 5 wt% or less, and is 0.01 to 99.99 wt%, 0.1 to 99.9 wt%, 0.1 to 50 wt%, 0.1 to 40 wt%, 0.1 to 30 wt%, 0.1 to 20 wt%, 0.1 to 10 wt%, 0.5 to 10 wt%, or 1 to 10 wt% relative to the total topical skin composition.

[0024] In one aspect of the present invention, the ultraviolet wavelength converting substance in the composition for external use on skin contains phycocyanin, and the preferred content of phycocyanin in the composition for external use on skin of the present invention is 0.00001% by weight or more, preferably 0.0001% by mass or more, and 20% by weight or less, preferably 15% by weight or less, more preferably 10% by weight or less, and even more preferably 5% by weight or less, based on the total amount of the composition for external use on skin. Furthermore, the content is 0.00001 to 99.99% by weight, 0.0001 to 99.9% by weight, 0.0001 to 50% by weight, 0.0001 to 40% by weight, 0.0001 to 30% by weight, 0.0001 to 20% by weight, 0.0001 to 10% by weight, 0.0001 to 5% by weight, 0.001 to 5% by weight, 0.01 to 5% by weight, 0.05 to 5% by weight, 0.1 to 5% by weight, 0.1 to 3% by weight, or 0.1 to 1% by weight, based on the total weight of the topical skin composition.

[0025] In one embodiment of the present invention, the ultraviolet wavelength converting substance in the composition for external use on skin contains vitamin B2, and the content of vitamin B2 in the composition for external use on skin of the present invention is preferably 0.00001% by weight or more, more preferably 0.0001% by weight or more, and 20% by weight or less, preferably 15% by weight or less, more preferably 10% by weight or less, and even more preferably 5% by weight or less, based on the total weight of the composition for external use on skin. The range is 0.00001 to 99.99% by weight, 0.0001 to 99.9% by weight, 0.0001 to 50% by weight, 0.0001 to 40% by weight, 0.0001 to 30% by weight, 0.0001 to 20% by weight, 0.0001 to 10% by weight, 0.0001 to 5% by weight, 0.001 to 5% by weight, 0.005 to 5% by weight, 0.01 to 5% by weight, 0.01 to 1% by weight, 0.01 to 0.5% by weight, or 0.01 to 0.1% by weight based on the total weight of the composition.

[0026] Cell activation includes, but is not limited to, promoting the metabolism and turnover of animal cells, including human cells, such as skin fibroblasts and / or keratinocytes, improving function, promoting proliferation, inhibiting oxidation, improving resistance to fatigue and external stimuli, inhibiting decline in function and activity, etc. Activating skin cells is expected to have effects such as preventing and improving wrinkles, age spots, skin aging, photoaging, etc.

[0027] The cell activation effect can be measured using Alamar, as described in Patent Document 1, for example. This may be carried out by measuring the viability, reducing capacity, or proliferation of live cells using Fluorescent Blue, or any other method can be used, such as other dye assays, mitochondrial membrane potential-dependent dye assays, intracellular cytochrome c assays, elastase-cleaved dye assays, ATP and ADE assays, glycolytic flux and oxygen consumption assays, collagen assays, photoaging assays, collagen glycation assays, assays for inflammatory substances (interleukin 1α, interleukin 8, tumor necrosis factor α, etc.), assays for skin barrier function-related proteins (corneodesmosin, sphingomyelin phosphodiesterase, filaggrin, involucrin, loricrin, transglutaminase 1, caspase 14, etc.), assays for angiogenesis regulators (VEGF-A, ANGPT1, etc.), assays for oxidation and / or skin stress-related proteins (aromatic hydrocarbon receptor repressor, cytochrome P4501B1, aromatic hydrocarbon receptor repressor, heme oxygenase 1, etc.), and hyaluronic acid assays.

[0028] The topical skin composition of the present invention is suitable for exerting the functions of an ultraviolet wavelength conversion substance and is suitable for activating cells to mitigate or more actively improve or recover skin damage during and after ultraviolet irradiation. More specifically, it is suitable for suppressing collagen production by fibroblasts and the like, hyaluronic acid production, and damage caused by photoaging, as well as for suppressing oxidative stress in keratinocytes and the like, enhancing barrier function, suppressing inflammatory responses, and further suppressing collagen glycation and angiogenesis in the skin.

[0029] The fluorescence intensity can be measured, for example, by irradiating a plate containing the topical skin composition with ultraviolet light and measuring the fluorescence intensity using a spectrofluorometer. Alternatively, a coating film of the composition can be formed on the surface of a substrate and then irradiated with ultraviolet light and the fluorescence intensity can be measured using a spectrofluorometer. The substrate can be a resin substrate such as polymethyl methacrylate (PMMA), nylon, or acrylic plate, or an inorganic plate such as glass or quartz. For example, a PMMA plate with a V-shaped groove on its surface (also known as an "S plate"; see Japanese Patent No. 4453995) can be used. The fluorescence intensity can be measured as the fluorescence value at a specific single wavelength or as the integrated value within a specific wavelength range.

[0030] (B) Alkylene oxide derivative In the present invention, it is particularly preferable to use an alkylene oxide derivative, and among these, an alkylene oxide derivative represented by the following formula (I): R １ O-[(EO) ｍ (AO) ｎ ]-R ２ (I) (In the formula, AO is an oxyalkylene group having 3 to 4 carbon atoms, EO is an oxyethylene group, m and n are the average number of moles of the oxyethylene group and the oxyalkylene group added, respectively, and 1≦m≦70, 1≦n≦70. The ratio of oxyethylene groups to the total of oxyalkylene groups having 3 to 4 carbon atoms and oxyethylene groups is 20 to 80 mass% (0.2≦m / (m+n)≦0.8). The oxyalkylene groups having 3 to 4 carbon atoms and oxyethylene groups may be added in a block form or in a random form. R １ and R ２ are the same or different hydrocarbon groups having 1 to 4 carbon atoms or hydrogen atoms, and R １ and R ２ The ratio of the number of hydrogen atoms to the number of hydrocarbon groups is 0.15 or less on average.

[0031] In the alkylene oxide derivative of formula (I), AO is an oxyalkylene group having 3 to 4 carbon atoms, and specific examples include an oxypropylene group, an oxybutylene group, an oxyisobutylene group, an oxytrimethylene group, and an oxytetramethylene group. Preferred examples include an oxypropylene group and an oxybutylene group. EO is an oxyethylene group. m is the average number of moles of oxyethylene groups added, and is 1≦m≦70, preferably 2≦m≦50. n is the average number of moles of oxyalkylene groups having 3 to 4 carbon atoms added, and is 1≦n≦70, preferably 5≦n≦55.

[0032] The proportion of oxyethylene groups to the total of oxyalkylene groups having 3 to 4 carbon atoms and oxyethylene groups is preferably 20 to 80% by mass. The order in which ethylene oxide and alkylene oxide having 3 to 4 carbon atoms are added is not particularly specified. The oxyethylene groups and oxyalkylene groups having 3 to 4 carbon atoms may be added in a block fashion or randomly. Preferably, they are added in a random fashion.

[0033] R １ and R ２ R is a hydrocarbon group having 1 to 4 carbon atoms or a hydrogen atom, and examples of the hydrocarbon group include alkyl groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, and tert-butyl. Methyl and ethyl groups are preferred. Hydrocarbon groups having 5 or more carbon atoms tend to reduce the effects of the present invention. １ , R ２ may be the same or different.

[0034] R １ and R ２ may be used alone, or may contain a mixture of hydrocarbon groups having 1 to 4 carbon atoms and hydrogen atoms, or may contain a mixture of hydrocarbon groups having 1 to 4 carbon atoms. １ and R ２ The ratio of hydrocarbon groups to hydrogen atoms in the hydrocarbon groups is such that the ratio Y / X of the number of hydrogen atoms (Y) to the number of hydrocarbon groups (X) is 0.15 or less on average, and preferably 0.06 or less on average.

[0035] The alkylene oxide derivative of formula (I) can be produced by known methods, for example, by addition polymerization of ethylene oxide and an alkylene oxide having 3 to 4 carbon atoms to a compound having a hydroxyl group, followed by etherification with an alkyl halide in the presence of an alkali catalyst.

[0036] Specific examples of the alkylene oxide derivative of formula (I) include POE (9) POP (2) dimethyl ether, POE (14) POP (7) dimethyl ether, POE (10) POP (10) dimethyl ether, POE (6) POP (14) dimethyl ether, POE (15) POP (5) dimethyl ether, POE (25) POP (25) dimethyl ether, POE (7) POP (12) dimethyl ether, POE (22) POP (40) dimethyl ether, POE (35) POP (40) dimethyl ether, POE (50) POP (40) dimethyl ether, POE (55) POP (30) dimethyl ether, POE Examples of suitable dimethyl ethers include (30) POP (34) dimethyl ether, POE (25) POP (30) dimethyl ether, POE (27) POP (14) dimethyl ether, POE (55) POP (28) dimethyl ether, POE (36) POP (41) dimethyl ether, POE (7) POP (12) dimethyl ether, POE (17) POP (4) dimethyl ether, POE (9) POB (2) dimethyl ether, POE (14) POB (7) dimethyl ether, POE (10) POP (10) diethyl ether, POE (10) POP (10) dipropyl ether, and POE (10) POP (10) dibutyl ether. In the present invention, polyoxyethylene (POE) / polyoxypropylene (POP) dimethyl ether is preferably used, but is not limited to these. The above POE, POP, and POB are abbreviations for polyoxyethylene, polyoxypropylene, and polyoxybutylene, respectively.

[0037] In the present invention, one or more alkylene oxide derivatives can be arbitrarily selected and used. However, it is particularly preferable to include polyoxyethylene / polyoxypropylene dimethyl ether, which is an alkylene oxide derivative of formula (I), and in particular, random polyoxyethylene (14) polyoxypropylene (7) dimethyl ether.

[0038] The content of the alkylene oxide derivative in the topical skin composition of the present invention is preferably 0.1 wt% or more, preferably 0.5 wt% or more, more preferably 1 wt% or more, and 20 wt% or less, preferably 10 wt% or less, more preferably 5 wt% or less, and is 0.01 to 99.99 wt%, 0.1 to 99.9 wt%, 0.1 to 20 wt%, 0.1 to 10 wt%, 0.1 to 5 wt%, 0.5 to 20 wt%, 0.5 to 10 wt%, 0.5 to 5 wt%, 1 to 20 wt%, 1 to 10 wt%, or 1 to 5 wt% based on the total weight of the topical skin composition.

[0039] (Other Components) The topical skin composition of the present invention may contain the following components: (1) Ultraviolet absorber Ultraviolet absorbers absorb incident ultraviolet light and are therefore thought to indirectly inhibit the function of ultraviolet wavelength conversion substances. However, surprisingly, the topical skin composition of the present invention can contain an ultraviolet absorber and can exhibit the function of an ultraviolet wavelength conversion substance.

[0040] The topical skin composition of the present invention contains an ultraviolet absorber. The ultraviolet absorber is a substance that absorbs ultraviolet rays, converts them into energy such as heat or infrared rays, and then emits the energy. The ultraviolet absorber that can be used in the present invention is not particularly limited as long as it does not directly impair the function of the ultraviolet wavelength converting substance, and examples thereof include salicylic acid-based ultraviolet absorbers such as homomenthyl salicylate, ethylhexyl salicylate (octyl salicylate), homosalate, and triethanolamine salicylate; and cinnamic acid-based ultraviolet absorbers such as 2-ethylhexyl paramethoxycinnamate, glyceryl di-paramethoxycinnamate mono-2-ethylhexanoate, methyl 2,5-diisopropylcinnamate, 2,4,6-tris[4-(2-ethylhexyloxycarbonyl)anilino]-1,3,5-triazine (hereinafter also referred to as "ethylhexyl triazone"), methyl bis(trimethylsiloxy)silylisopentyl trimethoxycinnamate, a mixture of isopropyl paramethoxycinnamate and diisopropylcinnamate, and diethanolamine p-methoxyhydrocinnamate; Benzoylmethane-based ultraviolet absorbers such as 2-phenyl-benzimidazole-5-sulfuric acid, 4-isopropyldibenzoylmethane, and 4-tert-butyl-4'-methoxydibenzoylmethane; octocrylene, polysilicone-15, 2-ethylhexyl dimethoxybenzylidene dioxoimidazolidinepropionate, 1-(3,4-dimethoxyphenyl)-4,4-dimethyl-1,3-pentanedione, cinoxate, methyl-O-aminobenzoate, 3-(4-methylbenzylidene)camphor, octyl triazone, diethylaminohydroxybenzoylhexyl benzoate, bisethylhexyloxyphenol methoxyphenyl triazine, and methylenebisbenzotriazolyltetramethylbutylphenol; and one or more selected from these may be contained in the topical skin composition.

[0041] The total content of ultraviolet absorbers that can be contained in the topical skin composition of the present invention is 0.5 wt% or more, preferably 1 wt% or more, more preferably 5 wt% or more, even more preferably 8 wt% or more, and most preferably 10 wt% or more, based on the total composition for topical skin, in order to function as a sunscreen, and 40 wt% or less, preferably 30 wt% or less, more preferably 25 wt% or less, and even more preferably 20 wt% or less, based on the total composition for topical skin, in order to avoid excessive absorption of ultraviolet rays contained in incident light. The total content of ultraviolet absorbers that can be contained in the topical skin composition of the present invention ranges from 0.5 to 40 wt%, 1 to 40 wt%, 1 to 30 wt%, 1 to 25 wt%, 1 to 20 wt%, 5 to 40 wt%, 5 to 30 wt%, 5 to 25 wt%, 5 to 20 wt%, 8 to 30 wt%, 8 to 25 wt%, or 8 to 20 wt%.

[0042] (2) Ultraviolet Scattering Agents Ultraviolet scattering agents scatter incident ultraviolet light and are therefore thought to indirectly inhibit the function of ultraviolet wavelength conversion substances. However, surprisingly, the topical skin composition of the present invention can contain ultraviolet scattering agents and can exert the function of ultraviolet wavelength conversion substances.

[0043] The topical skin composition of the present invention may contain an ultraviolet scattering agent. An ultraviolet scattering agent refers to a substance that can protect the skin, etc. from ultraviolet rays by reflecting and scattering ultraviolet rays. Examples of ultraviolet scattering agent materials that can be used in the present invention include titanium oxide, zinc oxide other than component (A), iron oxide, zirconium oxide, aluminum oxide, etc. Further examples of ultraviolet scattering agents include microparticulates and composites of these materials. The ultraviolet scattering agent preferably contains one or more selected from titanium oxide and zinc oxide other than component (A).

[0044] The titanium oxide and zinc oxide used as the UV scattering agent may be the titanium oxide and zinc oxide commonly used in cosmetics, but preferably those with better dispersibility, for example, those whose surfaces have been subjected to a known surface treatment, specifically a hydrophobic treatment, as needed, can be contained in the composition for external use on skin.

[0045] Examples of surface treatment methods include silicone treatment with methylhydrogenpolysiloxane, methylpolysiloxane, etc.; fluorine treatment with perfluoroalkyl phosphate ester, perfluoroalcohol, etc.; amino acid treatment with N-acylglutamic acid, etc.; alkylalkoxysilane treatment with octyltriethoxysilane, octyltrimethoxysilane, etc.; stearic acid / aluminum hydroxide treatment; lecithin treatment; metal soap treatment; fatty acid treatment; alkyl phosphate ester treatment, etc. Of these, zinc oxide whose surface has been treated with silicone is preferably used.

[0046] The silicone used for the surface treatment is not limited, and examples thereof include various silicones such as methylpolysiloxane, methylphenylpolysiloxane, methylhydrogenpolysiloxane, methylcyclopolysiloxane, octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, dodecamethylcyclohexasiloxane, octamethyltrisiloxane, tetradecamethylhexasiloxane, dimethylsiloxane-methyl(polyoxyethylene)siloxane-methyl(polyoxypropylene)siloxane copolymer, dimethylsiloxane-methyl(polyoxyethylene)siloxane copolymer, dimethylsiloxane-methyl(polyoxypropylene)siloxane copolymer, dimethylsiloxane-methylcetyloxysiloxane copolymer, and dimethylsiloxane-methylstearoxysiloxane copolymer. Methylhydrogenpolysiloxane and methylpolysiloxane are preferred.

[0047] Of the UV scattering agents that can be contained in the external skin composition of the present invention, octyltriethoxysilane-treated zinc oxide can facilitate redispersion of precipitates and aggregates of metal compound particles with a high specific gravity.

[0048] The total content of ultraviolet scattering agents that can be contained in the topical skin composition of the present invention is 0.1 wt % or more, preferably 0.5 wt % or more, more preferably 1 wt % or more, even more preferably 5 wt % or more, and most preferably 10 wt % or more, relative to the total composition for topical skin in order to function as a sunscreen, and is 40 wt % or less, preferably 30 wt % or less, more preferably 25 wt % or less, and even more preferably 20 wt % or less, relative to the total composition for topical skin in order to avoid excessive scattering of ultraviolet rays contained in incident light. The range of the total content of the ultraviolet scattering agent that can be contained in the external skin composition of the present invention is 0.1 to 40 wt%, 0.1 to 30 wt%, 0.1 to 25 wt%, 0.1 to 20 wt%, 0.5 to 40 wt%, 0.5 to 30 wt%, 0.5 to 25 wt%, 0.5 to 20 wt%, 1 to 40 wt%, 1 to 30 wt%, 1 to 25 wt%, 1 to 20 wt%, 5 to 40 wt%, 5 to 30 wt%, 5 to 25 wt%, 5 to 20 wt%, 10 to 40 wt%, 10 to 30 wt%, 10 to 25 wt%, or 10 to 20 wt%.

[0049] (3) Powder The topical skin composition of the present invention may contain a powder. Powder refers to a solid substance that has been pulverized into very fine particles. The powder contained in the topical skin composition of the present invention is not particularly limited as long as it is one that is commonly used in cosmetics, and examples thereof include polymethyl methacrylate, crosslinked silicone / network silicone block copolymer, silica, hydrophobized talc, corn starch, and hydrophobized polyurethane. All or a portion of the powder is dispersed in the oil phase of the topical skin composition of the present invention.

[0050] The amount of powder that can be contained in the topical skin composition of the present invention is 0.01 wt% or more, preferably 0.05 wt% or more, more preferably 0.1 wt% or more, even more preferably 0.5 wt% or more, based on the total amount of the topical skin composition, and is 20 wt% or less, preferably 15 wt% or less, more preferably 10 wt% or less, even more preferably 5 wt% or less, and is 0.01 to 99.99 wt%, 0.1 to 99.9 wt%, 0.1 to 20 wt%, 0.1 to 15 wt%, 0.1 to 10 wt%, 0.5 to 20 wt%, 0.5 to 10 wt%, or 1 to 10 wt% based on the total amount of the topical skin composition.

[0051] (4) Dispersant The topical skin composition of the present invention may contain a dispersant. A dispersant refers to a substance that can adsorb to the surface of particles dispersed in an aqueous or oily phase, thereby allowing the particles to be uniformly dispersed in an aqueous or oily medium. The dispersant that can be used in the present invention is not particularly limited as long as it does not impair the function of the ultraviolet wavelength conversion substance. Oil-based dispersants are preferred, and examples of oil-based dispersants include nonionic surfactants, cationic surfactants, anionic surfactants, silicone-based surfactants, fatty acids, etc. In the present invention, the use of nonionic surfactants and / or silicone-based surfactants and / or fatty acids that are commonly used in cosmetics and pharmaceuticals is particularly preferred.

[0052] Preferred dispersing agents that can be included in the topical skin composition of the present invention include PEG-10 dimethicone, bisbutyldimethicone polyglyceryl-3, PEG-polydimethylpolysiloxane ethyl dimethicone, lauryl PEG-polydimethylpolysiloxane ethyl dimethicone, cetyl PEG / PPG-10 / dimethicone, isostearic acid, polyglyceryl-2 diisostearate, carboxydecyltrisiloxane, PEG-12 dimethicone, or polyoxyethylene sorbitan monostearate, or a combination of two or more thereof.

[0053] Preferred examples of dispersing agents that can be contained in the topical skin composition of the present invention, which enhance the function of the ultraviolet wavelength converting substance, include PEG-10 dimethicone, bisbutyldimethicone polyglyceryl-3, PEG-9 polydimethylpolysiloxyethyl dimethicone, lauryl PEG-9 polydimethylpolysiloxyethyl dimethicone, cetyl PEG / PPG-10 / 1 dimethicone, isostearic acid, carboxydecyltrisiloxane, or a combination of two or more thereof.

[0054] The content of the dispersant in the topical skin composition of the present invention is not particularly limited as long as it does not impair the wavelength conversion effect of the present invention, and can be appropriately determined depending on the type of ultraviolet wavelength conversion substance and the intended use of the topical skin composition containing the ultraviolet wavelength conversion substance, for example, within the range of 0.01 to 10 wt %, 0.1 to 99.9 wt %, etc.

[0055] The content of the dispersant in the topical skin composition of the present invention is preferably 0.1 wt% or more, preferably 0.3 wt% or more, more preferably 0.5 wt% or more, and 20 wt% or less, preferably 10 wt% or less, more preferably 5 wt% or less, and even more preferably 2 wt% or less, and is 0.01 to 99.99 wt%, 0.1 to 99.9 wt%, 0.1 to 20 wt%, 0.1 to 10 wt%, 0.1 to 5 wt%, 0.1 to 3 wt%, 0.1 to 2 wt%, 0.1 to 1 wt%, 0.5 to 10 wt%, 0.5 to 5 wt%, or 0.5 to 2 wt% based on the total.

[0056] In one embodiment of the present invention, the dispersant in the topical skin composition comprises bisbutyldimethicone polyglyceryl-3 (e.g., KF-6109 manufactured by Shin-Etsu Chemical Co., Ltd.), and the content of the dispersant in the topical skin composition is 0.1 wt% or more, preferably 0.3 wt% or more, more preferably 0.5 wt% or more, and 20 wt% or less, preferably 10 wt% or less, more preferably 5 wt% or less, and even more preferably 2 wt% or less, and is 0.01 to 99.99 wt%, 0.1 to 99.9 wt%, 0.1 to 20 wt%, 0.1 to 10 wt%, 0.1 to 5 wt%, 0.1 to 3 wt%, 0.1 to 2 wt%, 0.1 to 1 wt%, 0.5 to 10 wt%, 0.5 to 5 wt%, or 0.5 to 2 wt% based on the total topical skin composition.

[0057] (5) Oil The topical skin composition of the present invention contains an oil. The oil refers to a hydrophobic substance that is a component of the topical skin composition of the present invention and undergoes phase separation from water. The oil that can be used in the present invention is not particularly limited and includes, for example, at least one of hydrocarbon oil, ester oil, silicone oil, liquid oil, solid oil, and higher alcohol.

[0058] Examples of hydrocarbon oils include liquid paraffin, tetraisobutane, hydrogenated polydecene, olefin oligomer, isododecane, isohexadecane, squalane, and hydrogenated polyisobutene.

[0059] The ester oil includes alkyl benzoate (C １２－１５ ), diisopropyl sebacate, octyl palmitate, cetyl isooctanoate (cetyl 2-ethylhexanoate), triethylhexanoin, neopentyl glycol dicaprate, triisostearin, diisostearyl malate, PPG-3 dipivalate, di-2-ethylhexyl succinate, 2-ethylhexyl 2-ethylhexanoate, polyglyceryl-6 octacaprylate, and tri(caprylic / capric acid)glyceryl.

[0060] Examples of silicone oils include caprylyl methicone, dimethicone, amino-modified polysiloxane, polyether-modified polysiloxane, alkyl-modified polysiloxane, and fluorine-modified polysiloxane.

[0061] Examples of liquid oils include avocado oil, camellia oil, macadamia nut oil, mink oil, olive oil, castor oil, jojoba oil, triglycerin, glycerin trioctanoate, and isostearic acid.

[0062] Examples of solid fats and oils include coconut oil, hardened coconut oil, palm oil, beef tallow, mutton tallow, Japan wax, and hardened castor oil.

[0063] Examples of higher alcohols include isostearyl alcohol, oleyl alcohol, and copolymers of butylene glycol and propylene glycol (for example, PBG / PPG-9 / 1 copolymer).

[0064] The total oil content of the topical skin composition of the present invention is 5% by weight or more, preferably 10% by weight or more, and more preferably 15% by weight or more, based on the total weight of the topical skin composition.

[0065] (6) Oil Phase Thickener The topical skin composition of the present invention may contain an oil phase thickener. An oil phase thickener is an additive that can increase the viscosity of the oil phase liquid by dissolving it in the oil phase of the topical skin composition. Examples of oil phase thickeners include inorganic polymers such as sugar fatty acid esters, solid oils, metal soaps, 12-hydroxystearic acid, bentonite, and hectorite (e.g., dimethyl distearyl ammonium hectorite). Examples of sugar fatty acid esters include esters of fatty acids having 10 to 22 carbon atoms with dextrin, sucrose (e.g., sucrose tetrastearate triacetate), inulin, etc., specifically dextrin palmitate, dextrin myristate, dextrin (palmitate / ethylhexanoate), dextrin stearate, dextrin behenate, dextrin laurate, coconut oil fatty acid dextrin, sucrose palmitate, sucrose stearate, inulin stearate, etc. Among these, sucrose tetrastearate triacetate, dimethyl distearyl ammonium hectorite, dextrin palmitate, dextrin myristate, dextrin (palmitate / ethylhexanoate), and inulin stearate are particularly preferred in terms of usability, stability, etc. One or more selected from these may be contained in the topical skin composition.

[0066] (7) Others The topical skin composition of the present invention can be appropriately blended with various ingredients as long as the effects of the present invention are not affected. Examples of the various ingredients include additives that are typically blended into cosmetics, such as powders ((spherical) silica, polymethyl methacrylate, crosslinked silicone / network silicone block copolymer, talc (which may be dimethicone-treated), corn starch, polyurethane, etc.), chelating agents (sodium edetate hydrate, etc.), fragrances, moisturizers other than (B) (glycerin, dipropylene glycol, PEG-6, etc.), preservatives, anionic surfactants, cationic surfactants, amphoteric surfactants, nonionic surfactants, moisturizers, water-soluble polymers, and siliconized polysaccharides. Examples of optional ingredients include film-forming agents such as acrylamide / DMAPA acrylate / methoxy PEG methacrylate copolymers, sequestering agents, lower alcohols, polyhydric alcohols, various extracts, sugars, amino acids, organic amines, polymer emulsions, pH adjusters, skin nutrients, vitamins, water-soluble agents applicable to pharmaceuticals, quasi-drugs, cosmetics, etc. (tranexamic acid, niacinamide, potassium 4-methoxysalicylate, dipotassium glycyrrhizinate, etc.), antioxidants, buffers, antioxidant aids, propellants, pigments, dyes, colorants, water, acidic components, alkaline components, etc. These optional ingredients can be blended appropriately into the oil phase and the aqueous phase. Furthermore, other cell activators, etc. may be contained or used in combination to enhance the effects of the present invention.

[0067] The topical skin composition of the present invention can be produced according to a conventional manufacturing method. Specifically, the topical skin composition of this embodiment can be obtained by the following procedure. Component (B) is mixed with water or the like to prepare an aqueous phase, and if component (A) or (A') is to be dispersed in the aqueous phase, component (B) is mixed with water or the like. An oily component such as oil is mixed with water to prepare an oily phase, and if component (A) or (A') is to be dispersed in the oily phase, component (B) is mixed with water or the like. The topical skin composition is obtained by adding the oily phase and other components to the aqueous phase and stirring.

[0068] The topical skin composition of the present invention includes sunscreen cosmetics such as sunscreen creams. The formulation may be, for example, emulsions, creams, etc. The topical skin composition of the present invention provides a refreshing feel when used compared to water-in-oil types, and has a unique, moist feel when applied to the skin, melting away like melting.

[0069] The topical composition for skin of the present invention can be used by applying, preferably coating, to the skin, particularly to the skin excluding hair, preferably to the face, body, hands, feet, etc. For example, applying, preferably coating, the topical composition for skin of this embodiment to the skin not only protects against ultraviolet rays and suppresses adverse effects on the skin, but also activates skin cells to give the skin a natural and desirable appearance.

[0070]

[0013] In one aspect of the present invention, an alkylene oxide derivative is used as an ultraviolet wavelength conversion function promoter. In the present invention, the term "ultraviolet wavelength conversion function promoter" refers to a compound that does not itself have ultraviolet wavelength conversion activity but can enhance the ultraviolet wavelength conversion function of an ultraviolet wavelength conversion substance in a composition containing the ultraviolet wavelength conversion substance.

[0071] The function of an alkylene oxide derivative as an ultraviolet wavelength conversion function promoter can be confirmed by adding the alkylene oxide derivative to a composition containing an ultraviolet wavelength conversion substance and observing an increase in fluorescence intensity when the composition is irradiated with ultraviolet light. Fluorescence intensity can be measured, for example, by measuring the fluorescence intensity when a plate containing a topical skin composition is irradiated with ultraviolet light using a spectrofluorometer. Alternatively, fluorescence intensity can be measured when a coating film of the composition is formed on the surface of a substrate and irradiated with ultraviolet light using a spectrofluorometer. The substrate can be a resin substrate such as polymethyl methacrylate (PMMA), nylon, or acrylic plate, or an inorganic plate such as glass or quartz. For example, a PMMA plate with a V-shaped groove on its surface (also known as an "S plate"; see Japanese Patent No. 4453995) can be used. Fluorescence intensity can be measured as the fluorescence value at a specific single wavelength or as the integrated value within a specific wavelength range.

[0072] As the alkylene oxide derivative used as the ultraviolet wavelength conversion function promoter of the present invention, it is particularly preferable to use an alkylene oxide derivative represented by the following formula (I): １ O-[(EO) ｍ (AO) ｎ ]-R ２ (I) (In the formula, AO is an oxyalkylene group having 3 to 4 carbon atoms, EO is an oxyethylene group, m and n are the average number of moles of the oxyethylene group and the oxyalkylene group added, respectively, and 1≦m≦70, 1≦n≦70. The ratio of oxyethylene groups to the total of oxyalkylene groups having 3 to 4 carbon atoms and oxyethylene groups is 20 to 80 mass% (0.2≦m / (m+n)≦0.8). The oxyalkylene groups having 3 to 4 carbon atoms and oxyethylene groups may be added in a block form or in a random form. R １ and R ２ are the same or different hydrocarbon groups having 1 to 4 carbon atoms or hydrogen atoms, and R １ and R ２ The ratio of the number of hydrogen atoms to the number of hydrocarbon groups is 0.15 or less on average.

[0073] In the alkylene oxide derivative of formula (I), AO is an oxyalkylene group having 3 to 4 carbon atoms, and specific examples include an oxypropylene group, an oxybutylene group, an oxyisobutylene group, an oxytrimethylene group, and an oxytetramethylene group. Preferred examples include an oxypropylene group and an oxybutylene group. EO is an oxyethylene group. m is the average number of moles of oxyethylene groups added, and is 1≦m≦70, preferably 2≦m≦50. n is the average number of moles of oxyalkylene groups having 3 to 4 carbon atoms added, and is 1≦n≦70, preferably 5≦n≦55.

[0074] The proportion of oxyethylene groups to the total of oxyalkylene groups having 3 to 4 carbon atoms and oxyethylene groups is preferably 20 to 80% by mass. The order in which ethylene oxide and alkylene oxide having 3 to 4 carbon atoms are added is not particularly specified. The oxyethylene groups and oxyalkylene groups having 3 to 4 carbon atoms may be added in a block fashion or randomly. Preferably, they are added in a random fashion.

[0075] R １ and R ２ R is a hydrocarbon group having 1 to 4 carbon atoms or a hydrogen atom, and examples of the hydrocarbon group include alkyl groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, and tert-butyl. Methyl and ethyl groups are preferred. Hydrocarbon groups having 5 or more carbon atoms tend to reduce the effects of the present invention. １ , R ２ may be the same or different.

[0076] R １ and R ２ may be used alone, or may contain a mixture of hydrocarbon groups having 1 to 4 carbon atoms and hydrogen atoms, or may contain a mixture of hydrocarbon groups having 1 to 4 carbon atoms. １ and R ２ The ratio of hydrocarbon groups to hydrogen atoms in the hydrocarbon groups is such that the ratio Y / X of the number of hydrogen atoms (Y) to the number of hydrocarbon groups (X) is 0.15 or less on average, and preferably 0.06 or less on average.

[0077] The alkylene oxide derivative of formula (I) can be produced by known methods, for example, by addition polymerization of ethylene oxide and an alkylene oxide having 3 to 4 carbon atoms to a compound having a hydroxyl group, followed by etherification with an alkyl halide in the presence of an alkali catalyst.

[0078] Specific examples of the alkylene oxide derivative of formula (I) include POE (9) POP (2) dimethyl ether, POE (14) POP (7) dimethyl ether, POE (10) POP (10) dimethyl ether, POE (6) POP (14) dimethyl ether, POE (15) POP (5) dimethyl ether, POE (25) POP (25) dimethyl ether, POE (7) POP (12) dimethyl ether, POE (22) POP (40) dimethyl ether, POE (35) POP (40) dimethyl ether, POE (50) POP (40) dimethyl ether, POE (55) POP (30) dimethyl ether, POE Examples of suitable dimethyl ethers include (30) POP (34) dimethyl ether, POE (25) POP (30) dimethyl ether, POE (27) POP (14) dimethyl ether, POE (55) POP (28) dimethyl ether, POE (36) POP (41) dimethyl ether, POE (7) POP (12) dimethyl ether, POE (17) POP (4) dimethyl ether, POE (9) POB (2) dimethyl ether, POE (14) POB (7) dimethyl ether, POE (10) POP (10) diethyl ether, POE (10) POP (10) dipropyl ether, and POE (10) POP (10) dibutyl ether. In the present invention, polyoxyethylene (POE) / polyoxypropylene (POP) dimethyl ether is preferably used, but is not limited to these. The above POE, POP, and POB are abbreviations for polyoxyethylene, polyoxypropylene, and polyoxybutylene, respectively.

[0079] In the present invention, one or more alkylene oxide derivatives can be arbitrarily selected and used. However, it is particularly preferable to include polyoxyethylene / polyoxypropylene dimethyl ether, which is an alkylene oxide derivative of formula (I), and in particular, random polyoxyethylene (14) polyoxypropylene (7) dimethyl ether.

[0080] The content of the alkylene oxide derivative as the ultraviolet wavelength conversion function promoter of the present invention in the composition containing an ultraviolet wavelength conversion substance is 0.1 wt % or more, preferably 0.5 mass % or more, more preferably 1 wt % or more, and 20 wt % or less, preferably 10 wt % or less, more preferably 5 wt % or less, based on the total weight of the composition, and is 0.01 to 99.99 wt %, 0.1 to 99.9 wt %, 0.1 to 20 wt %, 0.1 to 10 wt %, 0.1 to 5 wt %, 0.5 to 20 wt %, 0.5 to 10 wt %, 0.5 to 5 wt %, 1 to 20 wt %, 1 to 10 wt %, or 1 to 5 wt % based on the total weight of the composition.

[0081] Examples of ultraviolet wavelength converting substances for which the alkylene oxide derivative of the present invention acts as an ultraviolet wavelength converting function promoter include the following components: phycobiliproteins such as phycocyanin (allophycocyanin, C-phycocyanin, R-phycocyanin), phycoerythrocyanin, and phycoerythrin (B-phycoerythrin, b-phycoerythrin, C-phycoerythrin, R-phycoerythrin); vitamin A, β-carotene, vitamin K, vitamin B6, vitamin C; Naturally derived or synthetic ingredients such as vitamin B1, vitamin B2, vitamin B6, vitamin B12, folic acid, niacin, salicylic acid, lycopene, chili pepper extract, chili pepper pigment, paprika pigment, gardenia pigment, safflower pigment, turmeric pigment, cochineal pigment, perilla pigment, red cabbage pigment, flavonoids, carotenoids, quinoids, porphyrins, anthocyanins, polyphenols, etc.; Red No. 401, Red No. 227, Red No. 504, Red No. 218, Orange No. 2 dyes such as No. 05 P, Yellow No. 4, Yellow No. 5, Green No. 201, Pyranine Concentrate, Blue No. 1, 2,4-diaminophenoxyethanol hydrochloride, Alizurin Purple SS, Purple No. 401, Black No. 401, Herringdon Pink, Yellow No. 401, Benzidine Yellow G, Blue No. 404, Red No. 104, and meta-aminophenol; fluorescent substances obtained by doping inorganic compounds with fluorescence, such as amorphous silica particles described in Patent No. 6,424,656, cerium, phosphorus, and / or Examples of such phosphors include a blue phosphor containing magnesium and a red phosphor containing a compound obtained by activating a mixed crystal of an alkaline earth metal sulfide and a gallium compound with europium, as described in Japanese Patent No. 6361416; a zinc oxide phosphor as described in International Publication No. 2018 / 004006; a zinc oxide phosphor as described in Japanese Patent Application Laid-Open No. 2018-131422; and an inorganic phosphor as described in Japanese Patent Application Laid-Open No. 5-117127 (hereinafter, a phosphor derived from zinc oxide will be referred to as a "zinc oxide phosphor"). In one embodiment, the inorganic phosphor is ZnO:Zn,Zn １＋ｚ , ZnO １－ｘ A phosphor doped with a sulfur-containing compound such as a sulfide salt and / or sulfate, for example, zinc sulfide or zinc sulfate, as described in WO 2018 / 004006; MgTiO ３ , Mg ２ TiO ４Magnesium titanate phosphors obtained by doping magnesium titanate such as the above with manganese (hereinafter, phosphors derived from magnesium titanate will be referred to as "magnesium titanate phosphors"); and Ca(H ２ P.O. ４ ) ２ , CaHPO ４ , Ca ３ (P.O. ４ ) ２ The phosphor is one or more phosphors selected from calcium phosphate phosphors obtained by doping calcium phosphate with cerium, such as:

[0082] One aspect of the present invention is the use of an alkylene oxide derivative to promote the function of an ultraviolet wavelength conversion material. The alkylene oxide derivative can be added as a component of a composition containing an ultraviolet wavelength conversion material. As the alkylene oxide derivative, it is particularly preferable to use an alkylene oxide derivative represented by the following formula (I): R １ O-[(EO) ｍ (AO) ｎ ]-R ２ (I) (In the formula, AO is an oxyalkylene group having 3 to 4 carbon atoms, EO is an oxyethylene group, m and n are the average number of moles of the oxyethylene group and the oxyalkylene group added, respectively, and 1≦m≦70, 1≦n≦70. The ratio of oxyethylene groups to the total of oxyalkylene groups having 3 to 4 carbon atoms and oxyethylene groups is 20 to 80 mass% (0.2≦m / (m+n)≦0.8). The oxyalkylene groups having 3 to 4 carbon atoms and oxyethylene groups may be added in a block form or in a random form. R １ and R ２ are the same or different hydrocarbon groups having 1 to 4 carbon atoms or hydrogen atoms, and R １ and R ２ The ratio of the number of hydrogen atoms to the number of hydrocarbon groups is 0.15 or less on average.

[0083] The reason why the alkylene oxide derivative of the present invention exhibits such an excellent effect as an ultraviolet wavelength conversion function promoter is not clear; however, it is possible that the alkylene oxide derivative functions as a moisturizing agent and, due to its structure having two different properties, such as POE (14) and POP (7), enhances the affinity between the ultraviolet wavelength conversion substance and the base, allowing the ultraviolet wavelength conversion substance to be dispersed homogeneously in the base, thereby efficiently converting the wavelength of irradiated ultraviolet light.

[0084] The present invention will now be described in more detail with reference to examples, although the present invention is not limited thereto.

[0085] Example 1: Effect of POE(14)POP(7) dimethyl ether on ultraviolet wavelength conversion substances. Topical skin compositions (Formulation Examples A and B) with the compositions shown in Table 1 were produced according to a conventional manufacturing method. POE(14)POP(7) dimethyl ether used had oxypropylene groups and oxyethylene groups randomly attached. Each topical skin composition also contained an octyltriethoxysilane-treated zinc oxide phosphor as an ultraviolet wavelength conversion substance. The obtained topical skin compositions were irradiated with ultraviolet light at a wavelength of 365 nm, and the integrated fluorescence value at 400-600 nm was measured using a spectrofluorometer RF-5300PC (Shimadzu Corporation). When POE(14)POP(7) dimethyl ether, a known moisturizer, was added to Formulation Example A at a concentration of 2%, the integrated fluorescence value of the octyltriethoxysilane-treated zinc oxide phosphor, an ultraviolet wavelength conversion substance, increased significantly by 133% (Formulation Example B) (p<0.05 (n=5)). Furthermore, when the octyltriethoxysilane-treated zinc oxide phosphor was not included, the integrated fluorescence value did not increase even when 2% POE(14)POP(7) dimethyl ether was added, indicating that POE(14)POP(7) dimethyl ether itself did not function as an ultraviolet wavelength conversion substance.

[0086]

[0087] Example 2: Effect of moisturizer on ultraviolet wavelength conversion material (zinc oxide phosphor) Topical skin compositions (Formulation Examples C to F) with the compositions shown in Table 2 were prepared according to a conventional manufacturing method. Formulation Example C did not contain a moisturizer, while Formulation Example D contained 1% POE(14)POP(7) dimethyl ether (randomly added), Formulation Example E contained 2% glycerin, and Formulation Example F contained 2% PEG-6. Glycerin and PEG-6 enhanced the ultraviolet wavelength conversion function of the octyltriethoxysilane-treated zinc oxide phosphor, but the enhancement was not significant (p>0.05 (n=5)). However, even when the concentration of POE(14)POP(7) dimethyl ether was reduced to 1%, it significantly enhanced the ultraviolet wavelength conversion function of the octyltriethoxysilane-treated zinc oxide phosphor (p<0.005 (n=5)).

[0088]

[0089] Example 3: Effect of moisturizer on UV wavelength conversion substances (zinc oxide phosphor + phycocyanin) Skin topical preparations containing phycocyanin (DIC Corporation's LinaBlue), an organic fluorescent substance with long-wavelength fluorescence, together with zinc oxide phosphor were prepared according to a conventional manufacturing method (Formulations G and H). Formulation G contained no moisturizer, while Formulation H contained 2% POE(14)POP(7) dimethyl ether (randomly added). The resulting skin topical compositions were irradiated with UV light at a wavelength of 350 nm, and the integrated fluorescence values ​​from 400 to 800 nm were measured using a spectrofluorometer RF-5300PC (Shimadzu Corporation). POE(14)POP(7) dimethyl ether enhanced the UV wavelength conversion function of the octyltriethoxysilane-treated zinc oxide phosphor and LinaBlue (Table 3). Despite its relatively large molecular weight, POE(14)POP(7) dimethyl ether has the property of being infinitely miscible with both water and polar oils. Composed of two different properties, POE(14) and POP(7), it is thought that the affinity between the ultraviolet wavelength conversion substance and the base material may be increased, allowing the ultraviolet wavelength conversion substance to be dispersed homogeneously in the base material, resulting in efficient wavelength conversion of irradiated ultraviolet light.

[0090]

[0091] Although the embodiments of the topical skin composition and ultraviolet wavelength conversion function promoter of the present invention have been described above, the present invention is not limited to these and can be modified as appropriate within the scope of the invention.

Claims

1. (A) an ultraviolet wavelength converting material, and (B) An alkylene oxide derivative represented by the following general formula (I): A skin topical composition comprising: R １ -[[EO ｍ (AO) ｎ ]-R ２ (I) (In the formula, AO is an oxyalkylene group having 3 to 4 carbon atoms; EO is an oxyethylene group; The oxyalkylene group having 3 to 4 carbon atoms and the oxyethylene group may be added in a block form or a random form, m and n are the average molar numbers of the oxyethylene group and the oxyalkylene group added, respectively, and are 1≦m≦70, 1≦n≦70, and 0.2≦m / (m+n)≦0.8, R １ and R ２ are the same or different alkyl groups having 1 to 4 carbon atoms or hydrogen atoms, R １ and R ２ R relative to the number of alkyl groups １ and R ２ The ratio of the number of hydrogen atoms to the number of hydrogen atoms is 0.15 or less on average.

2. The composition for external use on skin according to claim 1, wherein the ultraviolet wavelength conversion substance is one or more selected from the group consisting of zinc oxide phosphor, magnesium titanate phosphor, and phycocyanin.

3. The composition for external use on the skin according to claim 1 or 2, wherein the ultraviolet wavelength conversion substance is zinc oxide phosphor and phycocyanin.

4. The composition for external application to skin according to claim 1 or 2, wherein the oxyalkylene groups and the oxyethylene groups of the alkylene oxide derivative are added randomly.

5. The composition for external application to skin according to claim 1 or 2, wherein the oxyalkylene group of the alkylene oxide derivative is an oxypropylene group.

6. R of the alkylene oxide derivative １ and R ２ The composition for external application to skin according to claim 1 or 2, wherein both are methyl groups.

7. The composition for external use on skin according to claim 1 or 2, comprising 1% by weight or more of the alkylene oxide derivative.

8. The composition for external application to skin according to claim 1 or 2, which is a water-in-oil type composition.

9. The composition for external application to skin according to claim 1 or 2, which is for cell stimulating purposes.

10. An ultraviolet wavelength conversion function promoter of an ultraviolet wavelength conversion substance, comprising an alkylene oxide derivative represented by the following general formula (I) as an active ingredient: R １ -[[EO ｍ (AO) ｎ ]-R ２ (I) (In the formula, AO is an oxyalkylene group having 3 to 4 carbon atoms; EO is an oxyethylene group; The oxyalkylene group having 3 to 4 carbon atoms and the oxyethylene group may be added in a block form or a random form, m and n are the average molar numbers of the oxyethylene group and the oxyalkylene group added, respectively, and are 1≦m≦70, 1≦n≦70, and 0.2≦m / (m+n)≦0.8, R １ and R ２ are the same or different alkyl groups having 1 to 4 carbon atoms or hydrogen atoms, R １ and R ２ R relative to the number of alkyl groups １ and R ２ The ratio of the number of hydrogen atoms to the number of hydrogen atoms is 0.15 or less on average.

11. The ultraviolet wavelength conversion function promoter according to claim 10, wherein the ultraviolet wavelength conversion substance is one or more selected from zinc oxide phosphor, magnesium titanate phosphor, and phycocyanin.

12. The ultraviolet wavelength conversion function promoter according to claim 10 or 11, wherein the oxyalkylene groups and the oxyethylene groups of the alkylene oxide derivative are added randomly.

13. The ultraviolet wavelength conversion function promoter according to claim 10 or 11, wherein the oxyalkylene group of the alkylene oxide derivative is an oxypropylene group.

14. R of the alkylene oxide derivative １ and R ２ The ultraviolet wavelength conversion function promoter according to claim 10 or 11, wherein both of are methyl groups.

15. Use of an alkylene oxide derivative represented by the following general formula (I) for promoting the function of an ultraviolet wavelength conversion material: R １ -[[EO ｍ (AO) ｎ ]-R ２ (I) (In the formula, AO is an oxyalkylene group having 3 to 4 carbon atoms; EO is an oxyethylene group; The oxyalkylene group having 3 to 4 carbon atoms and the oxyethylene group may be added in a block form or a random form, m and n are the average molar numbers of the oxyethylene group and the oxyalkylene group added, respectively, and are 1≦m≦70, 1≦n≦70, and 0.2≦m / (m+n)≦0.8, R １ and R ２ are the same or different alkyl groups having 1 to 4 carbon atoms or hydrogen atoms, R １ and R ２ R relative to the number of alkyl groups １ and R ２ The ratio of the number of hydrogen atoms to the number of hydrogen atoms is 0.15 or less on average.